Dopamine and insulin in psychosis trial
Treatments studied
Part of Mental health clinical trials.
This study looks at the relationship between dopamine and insulin in people with early psychosis who have not taken much antipsychotic medication. It aims to understand how these systems work together and may lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old.
- You have a body mass index (BMI) between 18 and 25.
- You are in good general health with no major medical issues.
- You do not regularly use alcohol or drugs (nicotine and caffeine are okay).
- You have been diagnosed with schizophrenia or schizophreniform disorder and have not taken antipsychotic medication for more than 2 weeks total.
- You are able to undergo an MRI and have no metal implants or other MRI exclusions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a nursing program to help people with early psychosis manage weight and reduce the risk of metabolic syndrome (a cluster of conditions that raise heart disease risk). It's designed for people who have had their first psychotic episode within the last 5 years.
This study tests whether unusual insulin action in the brain is linked to thinking problems and body/metabolic issues in schizophrenia. It may help researchers understand the cause and identify targets for future treatments.
This study tests whether a single dose of a common antipsychotic medication affects how the brain responds to insulin, which could help explain weight gain and metabolic side effects. Healthy young adults will receive either the antipsychotic or a placebo, then have their brain activity measured with an MRI.
This study looks at people with early psychosis who are about to start a new antipsychotic medication. It uses brain scans to understand how these medications work. If you are starting a new antipsychotic or changing your dose, this trial may be for you.
This study uses brain scans and a medication called methylphenidate (Ritalin) to understand how the brain chemical dopamine works in people at early risk for psychosis. It may help researchers find better ways to predict and treat psychosis.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
Hear when a new First Episode Psychosis (FEP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.